Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

ght, Director of Research and Development at GW. "We believe this clinical program demonstrates the flexibility and broad application of GW's cannabinoid platform to treat significant, unmet therapeutic needs." 

This study is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. The study objective is to assess the tolerability, safety and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ratio, in combination with temozolomide in patients with recurrent GBM. Secondary endpoints include additional pharmacokinetic and biomarker analyses and additional measurable outcomes of tumor response.

References:

i. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):319-32.
ii. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3(10):745-55.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world l
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized ... The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical ...
(Date:7/29/2015)... Windsor, CT (PRWEB) , ... July 29, 2015 ... ... of Biological Industries’ (BI) advanced cell culture products, announces the availability of BI’s ... Recently launched by Biological Industries, these stem cell differentiation media offer a complete ...
(Date:7/28/2015)... -- A n ew ... developing and commercialising innovative medicines to transform patient quality of ... experienced management team; blue chip ... BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces ... gross, from blue chip institutional investors and simultaneously acquired a ...
(Date:7/28/2015)... INCLINE VILLAGE, Nev. , July 28, 2015 /PRNewswire/ ... PDLI ) today announced that the Company will release ... ended June 30, 2015, on Wednesday, August 5, 2015, ... call and webcast that day at 4:30 p.m. Eastern ... relating to the call will be available via the ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... 7, 2011 MedWaves, AveCure™ microwave coagulation-ablation (MWA) ... soft-tissue lesions (abnormal structures) safely, effectively, precisely and ... one-thousand patients worldwide, including lesions in bone, kidney, ... bring its technology to treat lesions in other ...
... A whopping portfolio of 16 Nanotechnology products and ... Portfolio Release" organized to mark the fifty-second anniversary ... Releasing the portfolio, Director, Center of Excellence in ... this set of products and processes demonstrates potential ...
... progress in creating digital transistors using a material called ... the material,s use in computers and consumer electronics. ... electricity with little resistance or heat generation. After its ... in physics - it was touted as a potential ...
Cached Biology Technology:MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 3AIT unveils portfolio of 16 nanotechnology products 2Innovation is step toward digital graphene transistors 2
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... Biology Letters, Steve Brusatte, Professor Michael Benton, and ... did not proliferate immediately after they originated, but that ... driven by two mass extinctions. "The sheer ... was something special about these animals that preordained them ...
... of the gorgeously-decorated fish which throng Australia,s coral reefs and ... may well be written in their genes. Of particular ... able to re-colonise regions of reef devastated by global warming ... move south, says Dr Line Bay of the ARC Centre ...
... A groundbreaking poll finds that almost half of U.S. ... in 10 Americans say they have heard just a ... of synthetic biology, according to a new report released ... D. Hart Research. Both technologies involve manipulating matter ...
Cached Biology News:Mass extinctions and the evolution of dinosaurs 2Fishy future written in the genes 2Fishy future written in the genes 3Nanotech and synbio: Americans don't know what's coming 2
... Lacks the mycobacteria ... the side-effects. For this reason, Incomplete, ... injections. Freund's Adjuvants may be used to produce ... water-in-oil emulsions stimulate high and long-lasting antibody responses ...
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
ANTI GELSOLIN...
Biology Products: